FOXTROT™ PRO PTCA Gains Market Approval in Thailand

FOXTROT™ PRO PTCA Balloon Dilatation Catheter ("FOXTROT™ PRO PTCA"), a product in-house developed by Shanghai MicroPort Medical (Group) Co ("MicroPort^®"), recently received approval for market launch in Thailand. It is the first time that the product is permitted to launch in a non-European Union overseas market.

FOXTROT™ PRO PTCA is a rapid exchange balloon catheter for percutaneous transluminal coronary angioplasty ("PTCA"). It consists of an integrated shaft system and a balloon near the distal tip. The balloon is a semi-compliant balloon and is used for pre-dilatation of the stenotic atherosclerotic lesions of coronary artery diseases.

The device features thin balloon wall, low compliance and high burst pressure, which lead to its excellent pushability, traceability and crossability. Because of its small crossing profile, the product can be used as Kissing Balloon in 6F Catheter.

FOXTROT™ PRO PTCA is our new generation of balloon dilatation catheter. It received the CE Mark approval in March, 2015. As it is permitted to launch in Thailand, MicroPort^® will further expand our overseas market and diversify our cardiovascular product line.